Additionally, many very well set up adverse prognostic markers, together with U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their destructive influence in people treated with VO. The sole variable that remained predictive of the shorter progression-cost-free survival During this cohort